Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$4.01
+3.6%
$4.68
$3.79
$8.05
$1.17B0.361.36 million shs1.08 million shs
Amedisys, Inc. stock logo
AMED
Amedisys
$91.24
+0.9%
$92.72
$73.10
$96.44
$2.98B0.86283,240 shs159,362 shs
Certara, Inc. stock logo
CERT
Certara
$16.16
+1.4%
$17.79
$11.81
$24.70
$2.59B1.63540,276 shs568,264 shs
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
$7.33
+3.8%
$8.32
$5.53
$12.45
$831.59M1.39581,501 shs1.08 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+3.62%-4.07%-12.64%-24.48%-44.38%
Amedisys, Inc. stock logo
AMED
Amedisys
+0.93%-0.12%-0.99%-3.70%+15.86%
Certara, Inc. stock logo
CERT
Certara
+1.44%-7.34%-6.86%-1.40%-33.80%
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
+3.82%+3.39%-3.68%-20.67%-38.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.9572 of 5 stars
3.50.00.00.00.83.30.0
Amedisys, Inc. stock logo
AMED
Amedisys
3.0986 of 5 stars
1.13.00.05.03.21.71.3
Certara, Inc. stock logo
CERT
Certara
3.9877 of 5 stars
3.20.00.04.32.62.51.9
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
2.7472 of 5 stars
3.10.00.00.03.32.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
3.00
Buy$15.86295.44% Upside
Amedisys, Inc. stock logo
AMED
Amedisys
2.13
Hold$97.506.86% Upside
Certara, Inc. stock logo
CERT
Certara
2.36
Hold$20.0624.15% Upside
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
2.22
Hold$11.3154.33% Upside

Current Analyst Ratings

Latest CERT, DH, ABCL, and AMED Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Certara, Inc. stock logo
CERT
Certara
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$23.00
4/4/2024
Certara, Inc. stock logo
CERT
Certara
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
3/26/2024
Amedisys, Inc. stock logo
AMED
Amedisys
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
3/25/2024
Amedisys, Inc. stock logo
AMED
Amedisys
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$97.00 ➝ $100.00
3/1/2024
Certara, Inc. stock logo
CERT
Certara
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $20.00
3/1/2024
Certara, Inc. stock logo
CERT
Certara
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$14.00 ➝ $15.50
3/1/2024
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $11.00
2/29/2024
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$9.00 ➝ $10.00
2/26/2024
Certara, Inc. stock logo
CERT
Certara
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024
Certara, Inc. stock logo
CERT
Certara
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$19.00
2/22/2024
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$38.03M30.87N/AN/A$3.97 per share1.01
Amedisys, Inc. stock logo
AMED
Amedisys
$2.24B1.33$6.17 per share14.79$34.31 per share2.66
Certara, Inc. stock logo
CERT
Certara
$354.34M7.31$0.96 per share16.84$6.55 per share2.47
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
$251.42M3.43$3.21 per share2.28$10.31 per share0.71

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.40M-$0.52N/AN/AN/A-384.99%-12.36%-9.70%5/7/2024 (Confirmed)
Amedisys, Inc. stock logo
AMED
Amedisys
-$9.75M-$0.31N/A18.364.25-0.44%12.76%7.02%5/1/2024 (Estimated)
Certara, Inc. stock logo
CERT
Certara
-$55.36M-$0.35N/A46.171.64-15.62%4.33%2.98%5/7/2024 (Confirmed)
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
-$202.39M-$1.78N/A52.366.15-80.40%0.43%0.29%5/2/2024 (Estimated)

Latest CERT, DH, ABCL, and AMED Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.16N/A+$0.16N/AN/AN/A  
5/7/2024N/A
Certara, Inc. stock logo
CERT
Certara
$0.1030N/A-$0.1030N/AN/AN/A  
2/29/2024Q4 2023
Certara, Inc. stock logo
CERT
Certara
$0.09$0.05-$0.04$0.18$86.80 million$88.01 million
2/28/2024Q4 2023
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
$0.01-$0.01-$0.02$0.07$66.01 million$65.93 million
2/21/2024Q4 2023
Amedisys, Inc. stock logo
AMED
Amedisys
$1.04$0.94-$0.10$1.29$566.85 million$570.79 million  
2/20/2024Q4 2023
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.14-$0.17-$0.03-$0.17$9.58 million$9.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Amedisys, Inc. stock logo
AMED
Amedisys
N/AN/AN/AN/AN/A
Certara, Inc. stock logo
CERT
Certara
N/AN/AN/AN/AN/A
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
7.33
7.33
Amedisys, Inc. stock logo
AMED
Amedisys
0.32
1.05
1.05
Certara, Inc. stock logo
CERT
Certara
0.28
2.62
2.62
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
0.20
2.31
2.31

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Amedisys, Inc. stock logo
AMED
Amedisys
94.36%
Certara, Inc. stock logo
CERT
Certara
73.96%
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
98.67%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
32.45%
Amedisys, Inc. stock logo
AMED
Amedisys
1.80%
Certara, Inc. stock logo
CERT
Certara
2.60%
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
15.27%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
586292.78 million197.77 millionOptionable
Amedisys, Inc. stock logo
AMED
Amedisys
19,00032.67 million32.08 millionOptionable
Certara, Inc. stock logo
CERT
Certara
1,391160.19 million156.03 millionOptionable
Definitive Healthcare Corp. stock logo
DH
Definitive Healthcare
950117.79 million99.80 millionNot Optionable

CERT, DH, ABCL, and AMED Headlines

SourceHeadline
Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Recommendation of "Hold" by BrokeragesDefinitive Healthcare Corp. (NASDAQ:DH) Given Consensus Recommendation of "Hold" by Brokerages
americanbankingnews.com - April 23 at 2:30 AM
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Hold" by BrokeragesDefinitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Hold" by Brokerages
marketbeat.com - April 23 at 2:29 AM
Definitive Healthcare (NASDAQ:DH) Sees Unusually-High Trading VolumeDefinitive Healthcare (NASDAQ:DH) Sees Unusually-High Trading Volume
marketbeat.com - April 22 at 1:31 PM
Definitive Healthcare introduces Carevoyance sales enablement solution for medtech industryDefinitive Healthcare introduces Carevoyance sales enablement solution for medtech industry
finance.yahoo.com - April 16 at 4:28 PM
Head-To-Head Analysis: Xunlei (NASDAQ:XNET) vs. Definitive Healthcare (NASDAQ:DH)Head-To-Head Analysis: Xunlei (NASDAQ:XNET) vs. Definitive Healthcare (NASDAQ:DH)
americanbankingnews.com - April 13 at 1:30 AM
Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Increases By 54.0%Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Increases By 54.0%
marketbeat.com - April 12 at 10:21 PM
Definitive Healthcare Corp. (NASDAQ:DH) Shares Purchased by Vanguard Group Inc.Definitive Healthcare Corp. (NASDAQ:DH) Shares Purchased by Vanguard Group Inc.
marketbeat.com - April 11 at 4:11 AM
Conestoga Capital Advisors LLC Raises Holdings in Definitive Healthcare Corp. (NASDAQ:DH)Conestoga Capital Advisors LLC Raises Holdings in Definitive Healthcare Corp. (NASDAQ:DH)
marketbeat.com - April 10 at 3:55 PM
Riverbridge Partners LLC Sells 869,539 Shares of Definitive Healthcare Corp. (NASDAQ:DH)Riverbridge Partners LLC Sells 869,539 Shares of Definitive Healthcare Corp. (NASDAQ:DH)
marketbeat.com - April 5 at 2:00 PM
Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Drops By 35.3%Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Drops By 35.3%
marketbeat.com - March 29 at 11:21 AM
Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Hold" by BrokeragesDefinitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Hold" by Brokerages
marketbeat.com - March 29 at 2:29 AM
VML and Definitive Healthcare announce partnership to transform key opinion leader managementVML and Definitive Healthcare announce partnership to transform key opinion leader management
markets.businessinsider.com - March 22 at 9:25 PM
VML and Definitive Healthcare announce partnership to transform key opinion leader managementVML and Definitive Healthcare announce partnership to transform key opinion leader management
globenewswire.com - March 22 at 9:30 AM
Needham Reaffirms Their Hold Rating on Definitive Healthcare Corp (DH)Needham Reaffirms Their Hold Rating on Definitive Healthcare Corp (DH)
markets.businessinsider.com - March 21 at 5:03 PM
Definitive Healthcare Corp Class ADefinitive Healthcare Corp Class A
morningstar.com - March 20 at 8:52 PM
Definitive Healthcare: Reiterate Buy Rating As I Expect Growth To Recover In FY25Definitive Healthcare: Reiterate Buy Rating As I Expect Growth To Recover In FY25
seekingalpha.com - March 19 at 11:12 AM
DH Apr 2024 5.000 putDH Apr 2024 5.000 put
finance.yahoo.com - March 16 at 8:50 AM
DH Jul 2024 5.000 putDH Jul 2024 5.000 put
finance.yahoo.com - March 16 at 8:50 AM
Definitive Healthcare earns 2024 Middle Market Leader Award from Boston Business JournalDefinitive Healthcare earns 2024 Middle Market Leader Award from Boston Business Journal
globenewswire.com - March 14 at 3:53 PM
Definitive Healthcare Corp. (NASDAQ:DH) Just Released Its Annual Earnings: Heres What Analysts ThinkDefinitive Healthcare Corp. (NASDAQ:DH) Just Released Its Annual Earnings: Here's What Analysts Think
finance.yahoo.com - March 2 at 9:24 AM
Hold Rating on Definitive Healthcare Amid Leadership Changes and Revenue UncertaintiesHold Rating on Definitive Healthcare Amid Leadership Changes and Revenue Uncertainties
markets.businessinsider.com - March 1 at 7:55 PM
What 4 Analyst Ratings Have To Say About Definitive HealthcareWhat 4 Analyst Ratings Have To Say About Definitive Healthcare
markets.businessinsider.com - March 1 at 9:53 AM
Maintaining Hold on Definitive Healthcare Corp Amidst Transition and Mixed Growth SignalsMaintaining Hold on Definitive Healthcare Corp Amidst Transition and Mixed Growth Signals
markets.businessinsider.com - February 29 at 7:11 PM
Challenging Times For Definitive Healthcare: Analysts Highlight Sluggish Growth And Recovery Efforts In Q4 AnalysisChallenging Times For Definitive Healthcare: Analysts Highlight Sluggish Growth And Recovery Efforts In Q4 Analysis
markets.businessinsider.com - February 29 at 2:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbCellera Biologics logo

AbCellera Biologics

NASDAQ:ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Amedisys logo

Amedisys

NASDAQ:AMED
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Certara logo

Certara

NASDAQ:CERT
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Definitive Healthcare logo

Definitive Healthcare

NASDAQ:DH
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, and other organizations in the healthcare ecosystem. The company was founded in 2011 and is headquartered in Framingham, Massachusetts.